In early 1997, GeneTex, Inc. started operations in San Antonio, Texas. GeneTex was founded by three internationally renowned scientists with recognized expertise in clinical oncology, cancer biology and infectious diseases. Based on their breadth of experience and research interests, the company's initial focus was breast cancer biology and prognostic marker research. This evolved to incorporate a comprehensive portfolio of immunological reagents used by scientists studying the underlying mechanisms common to many forms of cancer. GeneTex’s product portfolio has expanded to cover research areas including cancer, cell biology, epigenetics, immunology, infectious disease, metabolism, neuroscience, signal transduction, stem cell development and zebrafish biology.
While commercial polyclonal and monoclonal antibodies have driven progress in science and medicine since their introduction, the generation of reliable antibodies remains an essential goal in the quest for data accuracy and reproducibility. On the forefront of high-quality antibody manufacturing, GeneTex has successfully incorporated recombinant monoclonal antibody technology into its product development platform. This technology has numerous well-documented advantages, with consistency of performance being of paramount significance. GeneTex’s capability in this area enhances its position in the research community and the biotechnology industry and spearheads its efforts to provide the most trusted antibody products available.